Categories Earnings, Health Care
Earnings Summary: Highlights of Charles River Laboratories’ Q3 2023 results
Pharma company Charles River Laboratories International, Inc. (NYSE: CRL) on Wednesday reported financial results for the third quarter of 2023.
- Revenue was $1.03 billion in the September quarter, an increase of 3.8% from $989.2 million last year
- Organic revenue rose 4.1%, driven primarily by the Discovery and Safety Assessment and Research Models and Services businesses
- Third-quarter net income decreased 9.4% annually to $87.4 million; earnings per share were $1.69, down 10.1%
- Adjusted net income increased to $140.5 million or $2.72 per share from $134.7 million or $2.63 per share in Q3 2022
- The management expects revenues to grow between 2.5% and 3.5% in fiscal 2023
- Organic revenue is estimated to increase in the range of 5.5% to $6.5%
- The company is looking for full-year earnings in the range of $7.30 per share to $7.50 per share
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
QCOM Earnings: Qualcomm Q2 2024 revenue and profit beat Street view
Semiconductor company Qualcomm, Inc. (NASDAQ: QCOM) reported an increase in earnings and revenues for the second quarter of 2024. The numbers came in above analysts' estimates. At $9.39 billion, March-quarter
Key takeaways from Amazon’s Q1 2024 earnings report
Amazon.com Inc. (NASDAQ: AMZN) had an upbeat start to fiscal 2024, delivering strong growth across the business in the first three months of the year. While the cloud segment continues
Key takeaways from Pfizer’s (PFE) Q1 2024 earnings report
Shares of Pfizer Inc. (NYSE: PFE) gained over 5% on Wednesday following the company’s announcement of its first quarter 2024 earnings results. Although the top and bottom line numbers decreased
